Ring-substituted hydroxynaphthanilides are considered as cyclic analogues of salicylanilides, compounds possessing a wide range of pharmacological activities, including promising anticancer properties. The aim of this study was to evaluate the potential anticancer effect of novel nitro-substituted hydroxynaphthanilides with a special focus on structure-activity relationships. The antiproliferative effect was assessed by Water Soluble Tetrazolium Salts-1 (WST-1) assay, and cytotoxicity was evaluated via dye exclusion test. Flow cytometry was used for cell cycle analysis and detection of apoptosis using Annexin V-FITC/PI assay. Protein expression was estimated by Western blotting. Our data indicate that the potential to cause the antiproliferative effect increases with the shift of the nitro substituent from the ortho- to the para-position. The most potent compounds, 3-hydroxy-N-(3-nitrophenyl)naphthalene-2-carboxamide (2), and 2-hydroxy-N-(4-nitrophenyl)-naphthalene-1-carboxamide (6) showed antiproliferative activity against THP-1 and MCF-7 cancer cells without affecting the proliferation of 3T3-L1 non-tumour cells. Compounds 2 and 6 induced the accumulation of THP-1 and MCF-7 cells in G1 phase associated with the downregulation of cyclin E1 protein levels, while the levels of cyclin B1 were not affected. Moreover, compound 2 was found to exert the pro-apoptotic effect on the THP-1 cells. These results suggest that hydroxynaphthanilides might represent a potential model structure for the development of novel anticancer agents.

Department of Chemical Drugs Faculty of Pharmacy University of Veterinary and Pharmaceutical Sciences Brno Palackeho 1946 1 612 42 Brno Czech Republic

Department of Human Pharmacology and Toxicology Faculty of Pharmacy University of Veterinary and Pharmaceutical Sciences Brno Palackeho 1946 1 612 42 Brno Czech Republic

Department of Pharmaceutical Chemistry Faculty of Pharmacy Comenius University Odbojarov 10 832 32 Bratislava Slovakia

Zobrazit více v PubMed

Kratky M., Vinsova J., Novotna E., Mandikova J., Wsol V., Trejtnar F., Ulmann V., Stolarikova J., Fernandes S., Bhat S., et al. Salicylanilide derivatives block mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase. Tuberculosis (Edinburgh) 2012;92:434–439. doi: 10.1016/j.tube.2012.06.001. PubMed DOI

Zadrazilova I., Pospisilova S., Masarikova M., Imramovsky A., Ferriz J.M., Vinsova J., Cizek A., Jampilek J. Salicylanilide carbamates: Promising antibacterial agents with high in vitro activity against methicillin-resistant staphylococcus aureus (MRSA) Eur. J. Pharm. Sci. 2015;77:197–207. doi: 10.1016/j.ejps.2015.06.009. PubMed DOI

Gonec T., Kos J., Zadrazilova I., Pesko M., Govender R., Keltosova S., Chambel B., Pereira D., Kollar P., Imramovsky A., et al. Antibacterial and herbicidal activity of ring-substituted 2-hydroxynaphthalene-1-carboxanilides. Molecules. 2013;18:9397–9419. doi: 10.3390/molecules18089397. PubMed DOI PMC

Gonec T., Kos J., Zadrazilova I., Pesko M., Keltosova S., Tengler J., Bobal P., Kollar P., Cizek A., Kralova K., et al. Antimycobacterial and herbicidal activity of ring-substituted 1-hydroxynaphthalene-2-carboxanilides. Bioorg. Med. Chem. 2013;21:6531–6541. doi: 10.1016/j.bmc.2013.08.030. PubMed DOI

Kos J., Zadrazilova I., Pesko M., Keltosova S., Tengler J., Gonec T., Bobal P., Kauerova T., Oravec M., Kollar P., et al. Antibacterial and herbicidal activity of ring-substituted 3-hydroxynaphthalene-2-carboxanilides. Molecules. 2013;18:7977–7997. doi: 10.3390/molecules18077977. PubMed DOI PMC

Olliaro P., Seiler J., Kuesel A., Horton J., Clark J.N., Don R., Keiser J. Potential drug development candidates for human soil-transmitted helminthiases. PLoS Negl. Trop. Dis. 2011;5:1219. doi: 10.1371/journal.pntd.0001138. PubMed DOI PMC

Mudduluru G., Walther W., Kobelt D., Dahlmann M., Treese C., Assaraf Y.G., Stein U. Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new targets. Drug Resist. Updat. 2016;26:10–27. doi: 10.1016/j.drup.2016.03.002. PubMed DOI

Osada T., Chen M., Yang X.Y., Spasojevic I., Vandeusen J.B., Hsu D., Clary B.M., Clay T.M., Chen W., Morse M.A., et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res. 2011;71:4172–4182. doi: 10.1158/0008-5472.CAN-10-3978. PubMed DOI PMC

Li Y., Li P.K., Roberts M.J., Arend R.C., Samant R.S., Buchsbaum D.J. Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. Cancer Lett. 2014;349:8–14. doi: 10.1016/j.canlet.2014.04.003. PubMed DOI PMC

Fonseca B.D., Diering G.H., Bidinosti M.A., Dalal K., Alain T., Balgi A.D., Forestieri R., Nodwell M., Rajadurai C.V., Gunaratnam C., et al. Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J. Biol. Chem. 2012;287:17530–17545. doi: 10.1074/jbc.M112.359638. PubMed DOI PMC

Lu W., Lin C., Roberts M.J., Waud W.R., Piazza G.A., Li Y. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway. PLoS ONE. 2011;6:1219. doi: 10.1371/journal.pone.0029290. PubMed DOI PMC

Jin Y., Lu Z., Ding K., Li J., Du X., Chen C., Sun X., Wu Y., Zhou J., Pan J. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: Inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res. 2010;70:2516–2527. doi: 10.1158/0008-5472.CAN-09-3950. PubMed DOI

Kang B.-R., Shan A.-L., Li Y.-P., Xu J., Lu S.-M., Zhang S.-Q. Discovery of 2-aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-ones as novel EGFR inhibitor by scaffold hopping. Bioorg. Med. Chem. 2013;21:6956–6964. doi: 10.1016/j.bmc.2013.09.027. PubMed DOI

Liechti C., Sequin U., Bold G., Furet P., Meyer T., Traxler P. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor. Eur. J. Med. Chem. 2004;39:11–26. doi: 10.1016/j.ejmech.2003.09.010. PubMed DOI

Deng W., Guo Z., Guo Y., Feng Z., Jiang Y., Chu F. Acryloylamino-salicylanilides as EGFR PTK inhibitors. Bioorg. Med. Chem. Lett. 2016;16:469–472. doi: 10.1016/j.bmcl.2005.06.088. PubMed DOI

Zhu X.F., Wang J.S., Cai L.L., Zeng Y.X., Yang D. SUCI02 inhibits the erbb-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells. Cancer Sci. 2006;97:84–89. doi: 10.1111/j.1349-7006.2006.00143.x. PubMed DOI PMC

Imramovsky A., Jorda R., Pauk K., Reznickova E., Dusek J., Hanusek J., Krystof V. Substituted 2-hydroxy-N-(arylalkyl)benzamides induce apoptosis in cancer cell lines. Eur. J. Med. Chem. 2016;68:253–259. doi: 10.1016/j.ejmech.2013.08.009. PubMed DOI

Zuo M., Zheng Y.W., Lu S.M., Li Y., Zhang S.Q. Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors. Bioorg. Med. Chem. 2012;20:4405–4412. doi: 10.1016/j.bmc.2012.05.034. PubMed DOI

Solomon V.R., Lee H. Quinoline as a privileged scaffold in cancer drug discovery. Curr. Med. Chem. 2011;18:1488–1508. doi: 10.2174/092986711795328382. PubMed DOI

Guo L., Wang Q.L., Jiang Q.Q., Jiang Q.J., Jiang Y.B. Anion-triggered substituent-dependent conformational switching of salicylanilides. New hints for understanding the inhibitory mechanism of salicylanilides. J. Org. Chem. 2007;72:9947–9953. doi: 10.1021/jo701823d. PubMed DOI

Walters Haygood C.L., Arend R.C., Gangrade A., Chettiar S., Regan N., Hassmann C.J., 2nd, Li P.K., Hidalgo B., Straughn J.M., Jr., Buchsbaum D.J. Niclosamide analogs for treatment of ovarian cancer. Int. J. Gynecol. Cancer. 2015;25:1377–1385. doi: 10.1097/IGC.0000000000000506. PubMed DOI

Brumatti G., Sheridan C., Martin S.J. Expression and purification of recombinant annexin V for the detection of membrane alterations on apoptotic cells. Methods. 2008;44:235–240. doi: 10.1016/j.ymeth.2007.11.010. PubMed DOI

Kumar S. Caspase function in programmed cell death. Cell Death Differ. 2007;14:32–43. doi: 10.1038/sj.cdd.4402060. PubMed DOI

Malik I., Bukovsky M., Andriamainty F., Galisinova J. Antimicrobial activity of meta-alkoxyphenylcarbamates containing substituted N-phenylpiperazine fragment. Braz. J. Microbiol. 2012;3:959–965. PubMed PMC

Williams G.H., Stoeber K. The cell cycle and cancer. J. Pathol. 2012;226:352–364. doi: 10.1002/path.3022. PubMed DOI

Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: A changing paradigm. Nat. Rev. Cancer. 2009;9:153–166. doi: 10.1038/nrc2602. PubMed DOI

Diaz-Moralli S., Tarrado-Castellarnau M., Miranda A., Cascante M. Targeting cell cycle regulation in cancer therapy. Pharmacol. Ther. 2013;138:255–271. doi: 10.1016/j.pharmthera.2013.01.011. PubMed DOI

Guo X., Hartley R.S. Hur contributes to cyclin E1 deregulation in MCF-7 breast cancer cells. Cancer Res. 2006;66:7948–7956. doi: 10.1158/0008-5472.CAN-05-4362. PubMed DOI

Wingate H., Bedrosian I., Akli S., Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle. 2003;2:461–466. doi: 10.4161/cc.2.5.464. PubMed DOI

Akli S., Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol. Ther. 2003;2:S38–S47. doi: 10.4161/cbt.201. PubMed DOI

Kollar P., Barta T., Zavalova V., Smejkal K., Hampl A. Geranylated flavanone tomentodiplacone B inhibits proliferation of human monocytic leukaemia (THP-1) cells. Br. J. Pharmacol. 2011;162:1534–1541. doi: 10.1111/j.1476-5381.2010.01171.x. PubMed DOI PMC

Kajstura M., Halicka H.D., Pryjma J., Darzynkiewicz Z. Discontinuous fragmentation of nuclear DNA during apoptosis revealed by discrete “sub-G1” peaks on DNA content histograms. Cytom. A. 2007;71:125–131. doi: 10.1002/cyto.a.20357. PubMed DOI

Dasari S., Tchounwou P.B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 2014;740:364–378. doi: 10.1016/j.ejphar.2014.07.025. PubMed DOI PMC

Liu L.F., Desai S.D., Li T.K., Mao Y., Sun M., Sim S.P. Mechanism of action of camptothecin. Ann. N. Y. Acad. Sci. 2000;922:1–10. doi: 10.1111/j.1749-6632.2000.tb07020.x. PubMed DOI

Stephenson D.A., Toltl L.J., Beaudin S., Liaw P.C. Modulation of monocyte function by activated protein C, a natural anticoagulant. J. Immunol. 2006;177:2115–2122. doi: 10.4049/jimmunol.177.4.2115. PubMed DOI

Amran D., Sancho P., Fernandez C., Esteban D., Ramos A.M., de Blas E., Gomez M., Palacios M.A., Aller P. Pharmacological inhibitors of extracellular signal-regulated protein kinases attenuate the apoptotic action of cisplatin in human myeloid leukemia cells via glutathione-independent reduction in intracellular drug accumulation. Biochim. Biophys. Acta. 2005;1743:269–279. doi: 10.1016/j.bbamcr.2004.10.009. PubMed DOI

McIlwain D.R., Berger T., Mak T.W. Caspase functions in cell death and disease. Cold Spring Harb. Perspect. Biol. 2013;5:a008656. doi: 10.1101/cshperspect.a008656. PubMed DOI PMC

Degterev A., Boyce M., Yuan J. A decade of caspases. Oncogene. 2003;22:8543–8567. doi: 10.1038/sj.onc.1207107. PubMed DOI

New potent N-hydroxycinnamamide-based histone deacetylase inhibitors suppress proliferation and trigger apoptosis in THP-1 leukaemia cells

Antimicrobial and ADME properties of methoxylated, methylated and nitrated 2-hydroxynaphthalene-1 carboxanilides

Salicylanilides and Their Anticancer Properties

Aminopeptidase N Inhibitors as Pointers for Overcoming Antitumor Treatment Resistance

Hybridization Approach to Identify Salicylanilides as Inhibitors of Tubulin Polymerization and Signal Transducers and Activators of Transcription 3 (STAT3)

Antistaphylococcal Activities and ADME-Related Properties of Chlorinated Arylcarbamoylnaphthalenylcarbamates

Consensus-Based Pharmacophore Mapping for New Set of N-(disubstituted-phenyl)-3-hydroxyl-naphthalene-2-carboxamides

Ring-Substituted 1-Hydroxynaphthalene-2-Carboxanilides Inhibit Proliferation and Trigger Mitochondria-Mediated Apoptosis

SAR-mediated Similarity Assessment of the Property Profile for New, Silicon-Based AChE/BChE Inhibitors

Bioactivity of Methoxylated and Methylated 1-Hydroxynaphthalene-2-Carboxanilides: Comparative Molecular Surface Analysis

Design and synthesis of anticancer 1-hydroxynaphthalene-2-carboxanilides with a p53 independent mechanism of action

Novel Benzene-Based Carbamates for AChE/BChE Inhibition: Synthesis and Ligand/Structure-Oriented SAR Study

Synthesis and Spectrum of Biological Activities of Novel N-arylcinnamamides

Proline-Based Carbamates as Cholinesterase Inhibitors

Photosynthesis-Inhibiting Activity of 1-[(2-Chlorophenyl)carbamoyl]- and 1-[(2-Nitrophenyl)carbamoyl]naphthalen-2-yl Alkylcarbamates

The Structure-Antimicrobial Activity Relationships of a Promising Class of the Compounds Containing the N-Arylpiperazine Scaffold

Synthesis and Antimicrobial Evaluation of 1-[(2-Substituted phenyl)carbamoyl]naphthalen-2-yl Carbamates